| GTO ID | GTC3031 |
| Trial ID | NCT05377307 |
| Disease | Large B-Cell Lymphoma | Follicular Lymphoma |
| Therapy | Gene transfer |
| Treatment | LV gene-edited immune cells |
| Recruitment status | Recruiting |
| Title | Long-term Follow-up Study to Evaluate the Safety and Efficacy in Patients Who Have Ever Received Lentiviral-based Gene-edited Immune Cell Therapy |
| Year | 2022 |
| Country | China |
| Company sponsor | Pell Bio-Med Technology Co., Ltd. |
| Other ID(s) | PLLV-LTFU-401 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||